natgillin/translations-raw huggingface dataset:
The European Commission granted a marketing authorisation valid throughout the European Union, for Hiprabovis IBR Marker Live to Laboratorios Hipra S.A. on 27 January 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Hiprabovis IBR Marker Live, veljavno po vsej Evropski uniji, odobrila družbi Laboratorios Hipra S.A. dne 27/01/2011.
The injections should be preferably administered on the alternate sides of the neck. 
Po možnosti naj se injiciranje opravlja izmenoma na obeh straneh vratu.
The studies also showed that the vaccine can be used in pregnant cattle as well in the presence of maternally derived antibodies. 
Študije so pokazale tudi, da se cepivo lahko uporablja pri brejih živalih, kot tudi ob prisotnosti maternalnih protiteles.
The safety of Hiprabovis IBR Marker Live was investigated in a number of laboratory studies and in one field trial that included dairy cows and fattening cattle. 
Varnost cepiva Hiprabovis IBR Marker Live je bila raziskana v številnih laboratorijskih študijah in v enem preskušanju na terenu, kjer so bile vključene krave molznice in govedo za pitanje.
It is a powder for suspension for injection that contains a modified live infectious bovine rhinotracheitis (IBR) virus (also known as Bovine Herpes Virus type 1). 
Na voljo je v obliki praška za suspenzijo za injiciranje, ki vsebuje prirejen živ virus infekcioznega bovinega rinotraheitisa (IBR), znanega tudi kot goveji herpes virus vrste 1).
Hiprabovis IBR Marker Live is a vaccine that contains an IBR virus that has been genetically modified to delete two genes so that the virus is less ‘pathogenic' (less able to cause a disease). 
Zdravilo Hiprabovis IBR Marker Live je cepivo, ki vsebuje genetsko spremenjen virus IBR z dvema izbrisanima genoma, zaradi česar je manj patogen (manj zmožen povzročiti bolezen).
What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)? 
Koliko časa mora preteči, preden se lahko žival zakolje in meso porabi za prehrano ljudi (karenca)?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Hiprabovis IBR Marker Live exceed the risks for the active immunisation of cattle from three months of age against Bovine Herpes Virus type 1 to reduce the clinical signs of infectious bovine IBR and field virus excretion and recommended that Hiprabovis IBR Marker Live be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Hiprabovis IBR Marker Live večje od z njim povezanih tveganj pri aktivni imunizaciji goveda od tretjega meseca starosti proti govejemu herpes virusu vrste 1 za zmanjšanje kliničnih znakov infekcioznega bovinega rinotraheitisa in izločanja virusa ter je priporočil, da se za zanj odobri dovoljenje za promet.
Live vaccine against infectious bovine rhinotracheitis (IBR) 
Živo cepivo proti infekcioznemu bovinemu rinotraheitisu (IBR)
Hiprabovis IBR Marker Live is used to vaccinate cattle (cows and calves) against the respiratory infections caused by IBR. 
Cepivo Hiprabovis IBR Marker Live se uporablja za cepljenje govedi (krav in telet) proti respiratornim okužbam, ki jih povzroča IBR.
The vaccine is used to reduce the clinical signs of IBR and the excretion (shedding) of the virus by the infected animals. 
Cepivo se uporablja za zmanjšanje kliničnih znakov IBR in izločanja virusa pri okuženih živalih.
The studies showed that the vaccine is safe for cattle from three months of age and that it reduces the clinical signs of IBR and field virus excretion. 
Študije so pokazale, da je cepivo varno od tretjega meseca dalje in da zmanjša klinične znake IBR ter izločanje virusa.
Hiprabovis IBR Marker Live is a vaccine. 
Zdravilo Hiprabovis IBR Marker Live je cepivo.
A field study also looked at the efficacy of Hiprabovis IBR Marker Live, compared with a dummy vaccine, on reducing the clinical signs of the disease and virus excretion. 
Terenska študija je raziskala tudi učinkovitost cepiva Hiprabovis IBR Marker Live pri zmanjševanju kliničnih znakov bolezni in izločanja virusa v primerjavi s cepivom brez aktivne učinkovine.
When Hiprabovis IBR Marker Live is given to cattle, the animals' immune systems recognise the viruses as ‘foreign' and make defences against it. 
Ko govedo cepimo, imunski sistem živali virus prepozna kot „tujek“ in proti njemu razvije obrambo.
Animals can also show a temporary inflammation at the site of injection in the 72 hours after-vaccination. 
V 72 urah po cepljenju se lahko pojavi tudi vnetje na mestu injiciranja.
Other information about Hiprabovis IBR Marker Live: 
Druge informacije o zdravilu Hiprabovis IBR Marker Live:
What benefit has Hiprabovis IBR Marker Live shown during the studies? 
Kakšne koristi je zdravilo Hiprabovis IBR Marker Live izkazalo med študijami?
Why has Hiprabovis IBR Marker Live been approved? 
Zakaj je bilo zdravilo Hiprabovis IBR Marker Live odobreno?
What is the risk associated with Hiprabovis IBR Marker Live? 
Kakšna tveganja so povezana z zdravilom Hiprabovis IBR Marker Live?
The withdrawal period is zero days. 
Obdobje karence zdravila je nič dni.
How has Hiprabovis IBR Marker Live been studied? 
Kako je bilo zdravilo Hiprabovis IBR Marker Live raziskano?
What is Hiprabovis IBR Marker Live used for? 
Za kaj se zdravilo Hiprabovis IBR Marker Live uporablja?
How does Hiprabovis IBR Marker Live work? 
Kako zdravilo Hiprabovis IBR Marker Live deluje?
What is Hiprabovis IBR Marker Live? 
Kaj je zdravilo Hiprabovis IBR Marker Live?
The European Commission issued a decision on 14 July 2009. 
Evropska komisija je odločbo izdala dne 14. julija 2009.
1 Article 29 of Directive 2001/83/EC as amended, referral on the grounds of potential serious risk to public health 
Člen 29 Direktive 2001/83/ES, kakor je bila spremenjena, napotitev na podlagi možnega resnega tveganja za javno zdravje.
Ref. EMEA/CHMP/499991/2009 EMEA/H/A-29/1061 
: EMEA/495517/2009 EMEA/H/A-29/1061
Prof Pirożynski (Poland) 
Prof. Pirożynski (Poljska)
The company wanted the authorisation to be recognised in Latvia, Lithuania, Poland, Slovakia and Slovenia (the ‘concerned Member States'). 
Družba je želela, da se odobritev za promet prizna v Latviji, Litvi, na Poljskem, Slovaškem in v Sloveniji (zadevne države članice).
Dr van Zwieten-Boot (Netherlands) 
Dr. van Zwieten-Boot (Nizozemska)
London, 16 July 2009 Doc. 
London, 16. julija 2009 Sklic dok.
The review was carried out under an ‘Article 29' referral1. 
Pregled je bil izveden v skladu z napotitvenim postopkom1.iz člena 29.
It can also be used in systemic infections (infections that affect the whole body), including tropical infections. 
Lahko se uporablja tudi pri sistemskih okužbah (ki prizadenejo celotno telo), vključno s tropskimi okužbami.
Referral start date: 
Datum začetka napotitve:
It can be used in local infections, such as infections of the vulva or vagina (female sexual organs) or infections of the skin or the eye. 
Lahko se uporablja pri lokalnih okužbah, kot so okužbe zunanjih ženskih spolovil ali nožnice (ženskih spolnih organov), okužbe kože ali očes.
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP was of the opinion that bioequivalence to the reference medicinal product has not been shown. 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave v okviru Odbora je CHMP menil, da biološka enakovrednost z referenčnim zdravilom ni bila dokazana.
However, because the concerned Member States were not able to reach an agreement, the Czech medicines regulatory agency referred the matter to the CHMP for arbitration on 31 July 2008. 
Ker pa omenjene države članice niso dosegle soglasja, je češki regulatorni organ dne 31. julija 2008 zadevo napotil na CHMP v arbitražo.
Questions and answers on the referral for Prokanazol capsules containing itraconazole 100 mg 
Vprašanja in odgovori v zvezi z napotitvijo za zdravilo Prokanazol kapsule, ki vsebujejo itrakonazol 100 mg
It is used to treat adults with infections caused by fungi. 
Uporablja se za zdravljenje odraslih z glivičnimi okužbami.
Why was Prokanazol reviewed? 
Zakaj je bilo zdravilo Prokanazol pregledano?
Prokanazol is a generic medicine that is based on a reference medicine authorised in the Czech Republic (Sporanox 100 mg capsules). 
Zdravilo Prokanazol je generično zdravilo, ki temelji na referenčnem zdravilu, odobrenem v Češki republiki (Sporanox 100 mg kapsule).
The company PRO.MED.CS Praha a. s. submitted Prokanazol for mutual recognition on the basis of the initial authorisation granted by the Czech Republic on 30 July 2003. 
Družba PRO.MED.CS Praha a. s. je predložila vlogo za medsebojno priznavanje zdravila Prokanazol na podlagi prvotnega dovoljenja za promet, odobrenega v Češki republiki dne 30. julija 2003.
The marketing authorisation in the Czech Republic should also be suspended. 
Dovoljenje za promet z zdravilom je treba preklicati tudi v Češki republiki.
Prokanazol can be used against a range of fungi and yeasts, including Candida, Aspergillus and Cryptococcus. 
Zdravilo Prokanazol se lahko uporablja za zdravljenja vrste gliv in kvasovk, vključno s kvasovko Candida, plesnijo Aspergillus in glivo Cryptococcus.
Prokanazol is an antifungal medicine. 
Prokanazol je protiglivično zdravilo.
Prokanazol is also marketed under the name Prokanaz. 
Zdravilo Prokanazol se trži tudi z imenom Prokanaz.
The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Prokanazol. 
Evropska agencija za zdravila je po nesoglasju med državami članicami Evropske unije (EU) glede odobritve zdravila Prokanazol zaključila arbitražni postopek.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Prokanazol do not outweigh its risks, and that the marketing authorisation granted in the Czech Republic cannot be recognised in other Member States of the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri Agenciji je zaključil, da koristi zdravila Prokanazol ne odtehtajo njegovih tveganj ter da se dovoljenje za promet z zdravilom, odobreno v Češki republiki, ne more priznati v drugih državah članicah EU.
The active substance in Prokanazol, itraconazole, is an antifungal substance that belongs to the group ‘triazoles'. 
Zdravilna učinkovina zdravila Prokanazol, itrakonazol, je protiglivično sredstvo, ki spada v skupino „triazolov“.
The grounds for the referral were that one of the concerned Member States, Poland, did not agree that enough evidence had been presented to show that Prokanazol was ‘bioequivalent' to the reference medicine. 
Napotitev je bila izvršena, ker se ena izmed zadevnih držav članic, Poljska, ni strinjala, da so predstavljeni dokazi o biološki enakovrednosti zdravila Prokanazol referenčnemu zdravilu zadostni.
The CHMP therefore concluded that the benefits of Prokanazol do not outweigh its risks and recommended that the marketing authorisation should not be granted in the concerned Member States. 
CHMP je zato zaključil, da koristi zdravila Prokanazol ne odtehtajo tveganj, povezanih z njim, in priporočil, da se dovoljenje za promet z zdravilom v zadevnih državah članicah ne odobri.
In addition, the Committee has also recommended that the marketing authorisation for Prokanazol in the Czech Republic should be suspended. 
Poleg tega je Odbor priporočil tudi, da je treba dovoljenje za promet z zdravilom v Republiki Češki preklicati.
What is Prokanazol? 
Kaj je zdravilo Prokanazol?
Company responses provided on: 15 December 2008 Opinion date: 
Datum izdaje mnenja:
Further information on Fiasp can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/fiasp. 
Nadaljnje informacije o zdravilu Fiasp so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/fiasp.
Fiasp received a marketing authorisation valid throughout the EU on 9 January 2017. 
Za zdravilo Fiasp je bilo 9. januarja 2017 izdano dovoljenje za promet, veljavno po vsej EU.
However, it is unclear whether this changes the risk of diabetic complications. 
Ni pa jasno, ali to privede do razlik v tveganju za zaplete zaradi sladkorne bolezni.
Diabetes is a disease in which blood glucose is high, either because the body cannot produce insulin (type 1 diabetes) or because the body does not make enough insulin or cannot use it effectively (type 2 diabetes). 
Sladkorna bolezen je bolezen, pri kateri je koncentracija glukoze v krvi visoka, bodisi zato, ker telo ne more proizvajati insulina (sladkorna bolezen tipa 1), bodisi zato, ker telo ne proizvede dovolj insulina oziroma ga ne more učinkovito uporabljati (sladkorna bolezen tipa 2).
What measures are being taken to ensure the safe and effective use of Fiasp? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Fiasp?
Although Fiasp was not studied in children below 2 years of age, it is also expected to have a beneficial effect in younger children. 
Čeprav zdravila Fiasp niso proučevali pri otrocih, mlajših od dveh let, naj bi to vseeno imelo koristne učinke pri mlajših otrocih.
It is usually injected under the skin of the belly or upper arm immediately before a meal, although it may be given up to 20 minutes after starting a meal if necessary. 
Običajno se injicira v podkožje trebuha ali nadlahti tik pred obrokom, po potrebi pa se lahko daje tudi v 20 minutah po začetku obroka.
The European Medicines Agency therefore decided that Fiasp's benefits outweigh the identified risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Fiasp večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about Fiasp 
Druge informacije o zdravilu Fiasp
Fiasp is a medicine that is used to treat children from one year of age and adults with diabetes. 
Fiasp je zdravilo, ki se uporablja za zdravljenje otrok, starejših od enega leta, in odraslih s sladkorno boleznijo.
As for all medicines, data on the use of Fiasp are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Fiasp stalno spremljajo.
(There was no direct comparison between Fiasp and another mealtime insulin in this study.) 
(V tej študiji niso neposredno primerjali zdravila Fiasp in drugega insulina za uporabo med obrokom.)
The slightly higher risk of hypoglycaemia at night in children treated with Fiasp is addressed in the product information and is considered manageable. 
Nekoliko večje tveganje za pojav hipoglikemije ponoči pri otrocih, zdravljenih z zdravilom Fiasp, je obravnavano v informacijah o zdravilu in velja za obvladljivo.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fiasp have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Fiasp upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
In two studies Fiasp was at least as effective as another insulin, NovoRapid. 
V dveh študijah se je zdravilo Fiasp izkazalo za vsaj enako učinkovito kot drug insulin, zdravilo NovoRapid.
Side effects reported with Fiasp are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Fiasp, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Insulin aspart enters the bloodstream faster than human insulin after injection and therefore works more quickly. 
Insulin aspart po injiciranju v krvni obtok vstopi hitreje kot humani insulin in zato deluje hitreje.
Why is Fiasp authorised in the EU? 
Zakaj je bilo zdravilo Fiasp odobreno v EU?
An overview of Fiasp and why it is authorised in the EU 
Pregled zdravila Fiasp in zakaj je odobreno v EU
The benefits of Fiasp were also shown in children. 
Koristi zdravila Fiasp so bile ugotovljene tudi pri otrocih.
What are the risks associated with Fiasp? 
Kakšna tveganja so povezana z zdravilom Fiasp?
Compared with the already authorised insulin aspart medicine NovoRapid, the lowering of blood glucose develops earlier in adults given Fiasp, although the total extent of the lowering effect is similar. 
V primerjavi z že odobrenim zdravilom, ki vsebuje insulin aspart, zdravilom NovoRapid, se koncentracija glukoze v krvi pri zdravilu Fiasp pri odraslih zniža hitreje, čeprav je celoten obseg zniževalnega učinka podoben.
The main measure of effectiveness was the medicine's ability to decrease the level in the blood of glycosylated haemoglobin (HbA1c), a substance which indicates how well blood glucose is controlled over time. 
Glavno merilo učinkovitosti je bila zmožnost zdravila, da zniža raven snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), kar kaže na to, kako dobro je glukoza v določenem časovnem obdobju uravnana v krvi.
What is Fiasp and what is it used for? 
Kaj je zdravilo Fiasp in za kaj se uporablja?
When injected under the skin, Fiasp should be used in combination with an intermediate- or long-acting insulin that is given at least once a day. 
Kadar se zdravilo Fiasp injicira v podkožje, se mora uporabljati v kombinaciji s srednjedolgodelujočim ali dolgodelujočim insulinom, ki se daje vsaj enkrat dnevno.
For more information about using Fiasp, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Fiasp glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The most common side effect with Fiasp (which may affect more than 1 in 10 people) is hypoglycaemia (excessively low blood sugar). 
Najpogostejši neželeni učinek zdravila Fiasp (ki se lahko pojavi pri več kot 1 bolniku od 10) je hipoglikemija (izjemno nizka koncentracija glukoze v krvi).
It contains the active substance insulin aspart, a rapid-acting insulin. 
Vsebuje učinkovino insulin aspart, tj. hitrodelujoči insulin.
Both Fiasp and NovoRapid contain insulin aspart but Fiasp contains some different ingredients intended to help it to be absorbed rapidly. 
Zdravili Fiasp in NovoRapid vsebujeta insulin aspart, vendar zdravilo Fiasp vsebuje še nekatere druge sestavine, ki mu pomagajo pri hitri absorpciji.
What benefits of Fiasp have been shown in studies? 
Kakšne koristi zdravila Fiasp so se pokazale v študijah?
Fiasp can also be used in a pump system for continuous insulin infusion under the skin or alternatively, it can be injected into a vein but only by a doctor or a nurse. 
Zdravilo Fiasp se lahko uporablja tudi v sistemu s črpalko za kontinuirano podkožno infundiranje insulina, lahko pa se daje tudi v veno, vendar to lahko počne le zdravnik ali medicinska sestra.
The benefits of Fiasp in reducing blood glucose as part of diabetes treatment have been shown in 4 main studies. 
Koristi zdravila Fiasp pri zniževanju koncentracije glukoze v krvi kot delu zdravljenja sladkorne bolezni so dokazali v štirih glavnih študijah.
The replacement insulin in Fiasp acts in the same way as the body's own insulin and helps glucose enter cells from the blood. 
Nadomestni insulin v zdravilu Fiasp deluje enako kot naravno tvorjeni insulin in pomaga pri prehodu glukoze iz krvi v celice.
This controls the level of blood glucose and reduces the symptoms and complications of diabetes. 
To pomaga uravnavati primerno koncentracijo glukoze v krvi ter zmanjša simptome in zaplete sladkorne bolezni.
The overall rate and severity of side effects was comparable with NovoRapid, although hypoglycaemia occurred more often in the first 2 hours after a dose of Fiasp. 
Celokupna stopnja in resnost neželenih učinkov sta primerljivi z zdravilom NovoRapid, vendar je v prvih dveh urah po odmerku zdravila Fiasp hitreje prišlo do hipoglikemije.
The dose depends on the patient's blood glucose, which should be tested regularly to find the dose that gives good control of blood sugar. 
Odmerek je odvisen od bolnikove koncentracije glukoze v krvi, ki jo je treba redno preverjati, da se določi najučinkovitejši odmerek za uravnavanje glukoze v krvi.
In patients given Fiasp the HbA1c fell after 18 weeks by 1.16 percentage points, compared with 0.22 points in those on long-acting insulin and metformin alone. 
Pri bolnikih, ki so prejemali zdravilo Fiasp, je vrednost HbA1c po 18 tednih upadla za 1,16 odstotne točke v primerjavi z 0,22 odstotne točke pri bolnikih, ki so prejemali samo dolgodelujoči insulin in metformin.
In this study, Fiasp was at least as effective as the comparator: there was almost no change in HbA1c in patients given Fiasp at mealtime (0.05 percentage points) and a similar slight increase in those given Fiasp after a meal or NovoRapid at mealtime (0.35 and 0.23 percentage points respectively). 
V tej študiji je bilo zdravilo Fiasp vsaj tako učinkovito kot primerjalno zdravilo: vrednost HbA1c je bila skoraj enaka pri bolnikih, ki so zdravilo Fiasp jemali med obrokom (0,05 odstotne točke), in podobno rahlo višja pri tistih, ki so to zdravilo vzeli po obroku ali ki so vzeli zdravilo NovoRapid med obrokom (0,35 oziroma 0,23 odstotne točke).
Hypoglycaemia can occur more quickly with Fiasp than with other mealtime insulins. 
Hipoglikemija se pri zdravilu Fiasp lahko pojavi hitreje kot pri drugih insulinih za uporabo med obrokom.
For the full list of side effects and restrictions of Fiasp, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Fiasp glejte navodilo za uporabo.
In the second study involving 689 adults with type 2 diabetes, the fall after 6 months of treatment (from a starting value of 7.96% and 7.89% respectively) was 1.38 points with Fiasp and 1.36 points with the comparator. 
V drugi študiji, ki je vključevala 689 odraslih bolnikov s sladkorno boleznijo tipa 2, je bil upad vrednosti po šestih mesecih zdravljenja (z začetnih vrednosti 7,96 % oziroma 7,89 %) 1,38 odstotne točke pri zdravilu Fiasp in 1,36 odstotne točke pri primerjalnem zdravilu.
How does Fiasp work? 
Kako zdravilo Fiasp deluje?
How is Fiasp used? 
Kako se zdravilo Fiasp uporablja?
One study involving 1,143 adults with type 1 diabetes whose starting HbA1c was around 7.6% found that after 6 months of treatment HbA1c fell by 0.32 percentage points with a mealtime dose of Fiasp, compared with 0.17 points with the other insulin. 
V eni študiji, ki je vključevala 1 143 odraslih bolnikov s sladkorno boleznijo tipa 1, pri katerih je bila začetna vrednost HbA1c okrog 7,6 %, so ugotovili, da se je vrednost HbA1c po šestih mesecih zdravljenja z odmerkom zdravila Fiasp med obrokom znižala za 0,32 odstotne točke v primerjavi z 0,17 odstotne točke z drugim insulinom.
A fourth study in 777 adolescents and children from 2 years of age with type 1 diabetes and a starting HbA1c of around 7.6% compared Fiasp (given at mealtime or 20 minutes after the start of the meal) with NovoRapid (given at mealtime). 
V četrti študiji, v katero je bilo vključenih 777 mladostnikov in otrok, starejših od dveh let, s sladkorno boleznijo tipa 1 in začetno vrednostjo HbA1c 7,6 %, so zdravilo Fiasp (ki so ga bolniki prejeli med obrokom ali 20 minut po začetku obroka) primerjali z zdravilom NovoRapid (ki so ga prejeli med obrokom).
A third study involving 236 adults with type 2 diabetes and a starting HbA1c of around 7.9% found that adding mealtime Fiasp to treatment with a long-acting insulin and the diabetes medicine metformin improved blood glucose control. 
V tretji študiji, ki je vključevala 236 bolnikov s sladkorno boleznijo tipa 2 in začetno vrednostjo HbA1c približno 7,9 %, so ugotovili, da je dodajanje zdravila Fiasp med obrokom k zdravljenju z dolgodelujočim insulinom in metforminom, drugim zdravilom za zdravljenje sladkorne bolezni, izboljšalo uravnavanje koncentracije glukoze v krvi.
Fiasp is a solution for injection available in vials, cartridges or pre-filled pens and can only be obtained with a prescription. 
Zdravilo Fiasp je raztopina za injiciranje, ki je na voljo v obliki vial, vložkov ali napolnjenih peresnikov.
A clinically relevant benefit in lowering blood glucose has been shown in studies with Fiasp. 
V študijah z zdravilom Fiasp so dokazali klinično pomembno korist pri zniževanju koncentracije glukoze v krvi.